According to the latest report by IMARC Group, titled “Hydroxychloroquine Market Size: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026″, the global hydroxychloroquine market exhibited strong growth during 2015-2020. Looking forward, IMARC Group expects the market to exhibit robust growth during 2021-2026.
Hydroxychloroquine (HCQ) is a derivative of chloroquine that is primarily used to treat or prevent malaria. It is also used in the treatment of numerous autoimmune diseases, such as systemic and discoid lupus erythematosus and rheumatoid arthritis. It exhibits endothelial stabilizing and anti-thrombotic effects as it containsantigens and cytokines.
Request Free Sample Report: https://www.imarcgroup.com/hydroxychloroquine-market/requestsample
Market Trends
The global market is majorly driven by the outbreak of the COVID-19 pandemic across the globe. Hydroxychloroquine has gained widespread prominence due to its effectiveness inthe treatmentof COVID-19 patients, thereby providing an impetus to the market growth. Furthermore, the increasing prevalence of malaria and other chronic disorders is providing a thrust to the market growth. Along with this, the rapidly rising cases of autoimmune diseases,and the escalating demand for generic drugs are further providing an impetus to the market growth. Other factors, including increasing investments by the governments of several countries to improve the overall healthcareinfrastructure and extensive research and development (RD) activities, are also projected to drive the market growth.
Our report has categorized the market based on dosage type, distribution, application, grade and route of administration.
Breakup by Dosage Type:
200 Mg300 Mg400 MgOthers
Breakup by Distribution:
Hospital PharmaciesRetail PharmaciesOthers
Breakup by Application:
Rheumatoid ArthritisLupus ErythematosusMalariaCoronavirus (COVID-19)Others
Breakup by Grade:
USP Standards GradeEP Standards GradePharmaceutical Standards GradeOthers
Breakup by Route of Administration:
OralIntravenous
Breakup by Region:
North America: (United States, Canada)Asia Pacific: (China, Japan,India, South Korea, Australia, Indonesia, Others)Europe: (Germany, France,United Kingdom, Italy, Spain, Russia, Others)Latin America: (Brazil, Mexico, Others)Middle East and Africa
Competitive Landscape Key Player:
Amneal Pharmaceuticals Inc.Cardinal Health Inc.Cipla Ltd.Ipca Laboratories Ltd.Laurus LabsLupin LimitedMylan N.V.Novartis AGPrasco LaboratoriesReddy’s Laboratories Ltd.Sanofi S.A.Teva Pharmaceutical Industries Ltd.Torrent PharmaZydus Cadila